Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 7Thoracic 1Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 118Myelodysplastic Syndromes 37Hodgkin Disease 35Leukemia, Myeloid, Acute 33Lymphoma 31Lymphoma, Non-Hodgkin 30Neoplasms, Plasma Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Myeloproliferative Disorders 19Hematologic Neoplasms 18Primary Myelofibrosis 17Recurrence 12Anemia, Aplastic 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Lymphoma, B-Cell, Marginal Zone 9Hematologic Diseases 9Burkitt Lymphoma 9Leukemia, Prolymphocytic 8Leukemia, Plasma Cell 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Polycythemia Vera 4Ovarian Neoplasms 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3

Interventions

selinexor 1pazopanib 1fludarabine 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × fludarabine × Plasma cell × Clear all
NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

University of Pennsylvania

Phase 1 Terminated
3 enrolled
DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡